Pharma — India Patent Cases
1,090 decisions indexed
Page 4 of 37 · 1,090 total
Vertex Pharmaceuticals Incorporated v.Deputy Controller Of Patents And Designs and Anr.
The petitioner, Vertex Pharmaceuticals Incorporated, filed an appeal against the Deputy Controller of Patents and Designs. The court addressed a preliminary issue regarding the maintainability of the matter raised by the respondent Controller.
Novartis AG v.Vachichem International Private Limited
The Plaintiffs, Novartis AG, filed a suit seeking a permanent injunction against Vachichem International Private Limited for infringing their Indian Patent No. 283133 covering Ribociclib. The court passed an order granting various exemptions and directing the appointment of a Local Commissioner to conduct an inventory and obtain accounts related to the alleged infringement.
Akums Drugs An Pharmaceuticals Limited v.Medivinc Healthcare Pvt Ltd & Anr.
The Delhi High Court addressed several interlocutory applications in the trademark infringement suit filed by Akums Drugs against Medivinc Healthcare. The court granted exemptions for various procedural requirements, including pre-institution mediation and advance service to defendants. Crucially, the court allowed the plaintiffs' application for an ex parte ad-interim injunction, directing the appointment of Local Commissioners to secure evidence and prevent further infringement.
Apex Laboratories Pvt.Ltd. v.Sunlife Sciences Private Limited
Apex Laboratories Pvt.Ltd filed a suit against Sunlife Sciences Private Limited alleging multiple infringements, including the use of a deceptively similar trademark (ZIMCOFIT) and copyright violation concerning product labels for their pharmaceutical products. The plaintiff sought permanent injunctions and damages based on both Trademark Act and Copyrights Act provisions. Ultimately, the parties reached an amicable settlement, which was subsequently recorded by the Madras High Court, leading to the decree of the suit.
Pharmacyclics Llc v.Deputy Controller Of Patents & Designs
Pharmacyclics Llc appealed the Deputy Controller's order rejecting its divisional patent application. The rejection was based on alleged scope changes and reliance on the parent application's claims. The High Court found that the divisional application should be treated as a substantive application, not bearing on the outcome of the parent, thus setting aside the impugned order.
Boehringer Ingelheim International GmbH & Anr. v.Femilab Healthcare & Anr.
Boehringer Ingelheim filed an application seeking permanent injunction to restrain Femilab Healthcare from infringing Patent No. 268846 related to Empagliflozin and its formulations. The court, relying on Supreme Court precedents (Novartis v. Natco), observed that the patent in issue had already expired. Consequently, the interim protection granted earlier was vacated.
Boehringer Ingelheim International GmbH v.Femilab Healthcare
The applicant sought an interim injunction against the respondents for infringing Patent No. 268846 related to Empagliflozin and its formulations. The court, however, noted that the subject patent had already expired, leading to the vacation of the existing interim protection.
Glaxosmithkline Pharmaceuticals Limited v.Chembott Chemicals And Pharmaceutical Private Limited and Anr
The Delhi High Court granted an ad-interim injunction in favor of Glaxosmithkline Pharmaceuticals against Chembott Chemicals. The court found that the plaintiff had made out a strong prima facie case regarding the infringement of its registered trademark, 'COBADEX', by the defendants' mark, 'COZIDEX'. Given the nature of pharmaceutical products and the potential for irreparable harm to both parties and the public, the injunction was granted immediately until the next hearing date.
Pstgems Private Limited v.Active Ayurvedic Life Private Limited & Ors.
The Delhi High Court granted the plaintiff, Pstgems Private Limited, an ex parte ad-interim injunction in a suit alleging infringement and passing off related to its trademark 'BRAMPIUM' and associated copyrights. The court recognized the urgency of the matter concerning counterfeit products and ordered the appointment of a Local Commissioner. This commissioner is tasked with accessing Defendant No. 1's premises, reviewing CCTV footage, and examining account books and stock registers to gather evidence of infringement.
Frimline Private Limited v.K-Smatco Lifesciences Private Limited
The Plaintiffs filed suit alleging that the Defendants are infringing upon their patented pharmaceutical composition, IN 382949, and also copying content from the Plaintiffs' website. The Suit Patent covers a synergistic combination of Lactoferrin and Guanosine Nucleotide for treating anaemia. Based on the prima facie evidence presented, the Court granted an ad-interim injunction restraining the Defendants from marketing or selling the infringing product 'FERROTOK PLUS', while also allowing interim protection for the Plaintiffs' copyright.
Pstgems Private Limited v.M/S Sonu Motor & Ors.
The Delhi High Court granted interim relief to Pstgems Private Limited in its suit against M/S Sonu Motor & Ors. The court allowed the plaintiff, a health tech company selling nutraceutical products, to proceed with urgent measures despite seeking exemptions from pre-institution mediation and advance service. Crucially, the court appointed Local Commissioners to conduct an inventory of the alleged infringing goods and packaging materials, paving the way for immediate enforcement against suspected trademark and copyright infringement.
Chugai Seiyaku Kabushiki Kaisha & Anr v.Anthem Biosciences Limited
The Plaintiffs filed a commercial suit seeking to restrain the Defendant from dealing in products that infringe their patent (IN 294424) related to Alectinib. The court addressed several interlocutory applications, including those for document production and exemption from mediation. In the main application for interim injunction, the Defendant provided an undertaking not to launch infringing products.
Pharmacyclics Llc v.Shilpa Medicare Limited
The suit was filed by Pharmacyclics Llc seeking permanent injunction against the infringement of Registered Patent No. 262968 by Shilpa Medicare Limited. The parties subsequently entered into a successful settlement agreement through mediation.
Sun Pharma Laboratories Limited v.Rambos Lifesciences Pvt Ltd
The Bombay High Court allowed Sun Pharma Laboratories Limited's leave petition seeking to consolidate the cause of action for passing-off with the existing claim of trademark infringement against Rambos Lifesciences Pvt Ltd. The court found that since both causes of action arose from the same set of transactions, combining them was appropriate. Furthermore, the interim relief previously granted in the matter was directed to continue until the next hearing date.
Glaxo Group Limited v.Aubade Healthcare Private Limited
The Delhi High Court granted an ex-parte ad-interim injunction in favor of Glaxo Group Limited against Aubade Healthcare Private Limited regarding trademark infringement and passing off. The court found that the Plaintiff had made out a prima facie case, demonstrating a balance of convenience, and noting the likelihood of irreparable harm if the Defendants were not restrained from using similar marks to 'ZENTEL.' This interim order is crucial for protecting the Plaintiff's brand integrity while the main suit proceeds.
Astellas Pharma Inc v.Everest Pharmaceuticals Limited
Astellas Pharma Inc filed a suit seeking permanent injunction and damages for the infringement of its Indian Patent No. 292990 by Everest Pharmaceuticals Limited and others. The court passed several orders, including granting an ex-parte ad-interim injunction against Defendants 8 and 9 to cease marketing and listing of the infringing product GILTERNIB.
Fdc Limited v.Healing Pharma India Private Limited
Fdc Limited filed a suit against Healing Pharma India Private Limited alleging multiple infringements related to its pharmaceutical products. The Delhi High Court issued an order addressing procedural aspects, including granting exemptions from pre-institution mediation and allowing the filing of additional documents. Crucially, the court also addressed interim relief, restraining the defendant from manufacturing or marketing products confusingly similar to Fdc's registered trademarks (ZIFI) and copyrighted trade dress (ELECTRAL).
Incyte Holdings Corporation v.Prajna Generics Private Limited
The Plaintiffs filed a suit seeking permanent injunction against the Defendant for infringing Indian Patent No. 269841, which covers Ruxolitinib compounds and their uses. The Court passed an order appointing a Local Commissioner to inspect the Defendant's premises, obtain accounts, and take samples of the alleged infringing drugs.
East India Pharmaceutical Works Limited v.Anil Keshrwani And Ors
The Calcutta High Court admitted the plaint filed by East India Pharmaceutical Works Limited against Anil Keshrwani and Ors. The court granted necessary procedural leaves, including exemption from pre-institution mediation.
Incyte Holdings Corporation & Ors. v.Aeon Formulations Pvt. Ltd.
The Plaintiffs, owners/licensees of Indian Patent No. 269841 covering Ruxolitinib compounds (used in treating Mye), filed a suit against Aeon Formulations Pvt. Ltd. seeking permanent injunction against infringement. The court passed an order granting various exemptions and appointing Local Commissioners to inspect the Defendant's premises, seize samples of the infringing drug, and gather evidence.
Akums Drugs And Pharmaceuticals Limited v.The Controller Of Patents & Anr.
Akums Drugs And Pharmaceuticals Limited filed an Appeal under Section 117A(4) of the Patents Act, 1970, challenging the order dated 26.12.2024 which rejected its patent application (No. 202211027823). The court also disposed of applications regarding exemption and condoned a delay of 110 days in filing the appeal.
F- Hoffmann -La Roche Ag & Anr v.Zydus Lifesciences Limited
The suit was filed seeking permanent injunction against infringement of two Indian patents related to Pertuzumab (Perjeta). The plaintiffs alleged that the defendant was manufacturing and selling a competing version. However, the court found that the plaintiffs failed to conduct necessary analytical characterization or reverse engineering of the defendant's product as required under Section 104A.
Novo Nordisk As v.Dr Reddys Laboratories Limited & Anr.
Novo Nordisk appealed an order passed by the learned Single Judge regarding an interim application in a patent dispute. The respondents argued they had a license to manufacture but not sell the impugned drug in India, reserving the right to export. The High Court disposed of the appeal, advancing the date for further consideration on the issue of export.
Chemo Healthcare Private Limited v.Examiner Of Trademarks & Anr.
The Gujarat High Court allowed Chemo Healthcare Private Limited's appeal against the rejection of its trademark registration for 'VILDAZE'. The court held that despite objections raised under Section 11(1) of the Trade Mark Act, 1999, the appellant was entitled to have the mark advertised. This decision allows the applicant to establish prior use and address any third-party opposition on its merits.
Brawn Biotech Ltd. v.Brawn Healthcare India P. Ltd.
The Delhi High Court has formally registered the trademark infringement suit filed by Brawn Biotech Ltd. against Brawn Healthcare India P. Ltd., following the failure of mediation proceedings to settle the dispute. The court has set out procedural timelines, including filing written statements and replication. Crucially, the court also granted notice for an ex-parte ad-interim injunction application, allowing the plaintiffs to seek immediate protection against alleged infringement of the 'BRAWN' trademark.
E. R. Squibb And Sons, Llc v.Zydus Lifesciences Limited
E. R. Squibb And Sons, Llc filed a suit seeking permanent injunction against Zydus Lifesciences Limited for infringing Indian Patent No. IN 340060, which covers the monoclonal antibody Nivolumab used in cancer treatment. The plaintiffs alleged that the defendant was planning to launch a bio-similar version (ZRC-3276) during the patent's term. The Delhi High Court granted an interim injunction, finding that the plaintiffs had established a prima facie case and irreparable loss would occur without immediate relief.
Sun Pharmaceutical Industries Ltd & Anr. v.Janricsan Pharma P Ltd & Ors.
The Delhi High Court granted an interim injunction in favor of Sun Pharmaceutical Industries Ltd against Janricsan Pharma P Ltd. The court found a prima facie case for trademark infringement, noting the potential for dangerous public confusion due to the similarity between the parties' pharmaceutical product names. This protective order restrains the defendants from manufacturing or selling products under marks deemed deceptively similar to the plaintiffs' registered trademarks until the final hearing.
Otsuka Pharmaceuticals Co.Ltd. v.Controller General Of Patents, Designs And Trademarks and Anr.
Otsuka Pharmaceuticals appealed a decision by the Deputy Controller of Patents which rejected its application for a patent related to aripiprazole microspheres. The core contention raised by Otsuka was that the rejection order lacked any reasoned justification, failing to discuss the invention or adequately address prior art documents (D1, D2, D3). The Calcutta High Court agreed with this assessment, finding the impugned order unreasoned and unsustainable.
Valary Lab Private Ltd v.G1 Therapeutics Inc & Anr.
The petitioner, Valary Lab Private Ltd, filed a petition seeking the revocation of Patent No. 434029 and an injunction against threats related to its alleged infringement. The court allowed applications for additional documents and granted notice to all parties. The case is set for re-notification on November 12, 2025.
Mankind Pharma Limited v.Kindwaves Healthcare Private Limited
In a trademark infringement suit, the Delhi High Court granted several interim reliefs favoring the plaintiff, Mankind Pharma Limited. The court allowed the appointment of a Local Commissioner to conduct an inventory of all products bearing the allegedly infringing mark 'KINDWAVES' at the defendant's premises. Furthermore, recognizing the urgency of the matter, the court exempted the plaintiff from mandatory pre-institution mediation and granted exemption from advance service, allowing the suit to proceed swiftly.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.